PLUR vs. ACHL, CASI, BCLI, CRTX, INAB, TARA, INKT, SRZN, NKGN, and ZIVO
Should you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Achilles Therapeutics (ACHL), CASI Pharmaceuticals (CASI), Brainstorm Cell Therapeutics (BCLI), Cortexyme (CRTX), IN8bio (INAB), Protara Therapeutics (TARA), MiNK Therapeutics (INKT), Surrozen (SRZN), NKGen Biotech (NKGN), and ZIVO Bioscience (ZIVO). These companies are all part of the "medical" sector.
Pluri (NASDAQ:PLUR) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, community ranking, analyst recommendations, earnings, risk, profitability and media sentiment.
Achilles Therapeutics received 17 more outperform votes than Pluri when rated by MarketBeat users.
Achilles Therapeutics has a consensus price target of $4.00, indicating a potential upside of 335.30%. Given Achilles Therapeutics' higher probable upside, analysts clearly believe Achilles Therapeutics is more favorable than Pluri.
16.6% of Pluri shares are owned by institutional investors. Comparatively, 56.4% of Achilles Therapeutics shares are owned by institutional investors. 24.3% of Pluri shares are owned by company insiders. Comparatively, 5.4% of Achilles Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Pluri has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.
Achilles Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -6,708.40%. Achilles Therapeutics' return on equity of -42.55% beat Pluri's return on equity.
Pluri has higher revenue and earnings than Achilles Therapeutics. Pluri is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Achilles Therapeutics had 3 more articles in the media than Pluri. MarketBeat recorded 3 mentions for Achilles Therapeutics and 0 mentions for Pluri. Achilles Therapeutics' average media sentiment score of 0.22 beat Pluri's score of -0.41 indicating that Achilles Therapeutics is being referred to more favorably in the news media.
Summary
Achilles Therapeutics beats Pluri on 11 of the 15 factors compared between the two stocks.
Get Pluri News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
